Fourth Swedish National Pension Fund

Egetis Therapeutics AB is a pharmaceutical drug development company based in Stockholm, Sweden, that specializes in late-stage projects targeting serious rare diseases with significant unmet medical needs, particularly within the orphan drug segment. The company is actively developing several innovative therapies, including PledOx, which is undergoing Phase III clinical trials to protect patients from chemotherapy-induced nerve damage while preserving the anticancer effects. Additionally, Egetis is working on Emcitate, a treatment for MCT8 deficiency, a rare genetic condition affecting thyroid hormone signaling, and Aladote, which aims to mitigate the risk of acute liver injury from acetaminophen poisoning. Founded in 2006, Egetis Therapeutics was previously known as PledPharma AB until its name change in December 2020.

Hansa Biopharma is a biopharmaceutical company focused on developing immunomodulatory treatments for individuals with rare immunological diseases. The company aims to create innovative therapies to address critical unmet medical needs in areas such as transplantation, autoimmune disorders, gene therapy, and oncology. Utilizing a proprietary antibody-cleaving enzyme technology platform, Hansa Biopharma targets pathogenic antibodies to enhance treatment outcomes. One of its key product candidates, imlifidase, is designed to facilitate kidney transplantation in sensitized patients and is also being explored for other organ and tissue transplantations, as well as acute autoimmune conditions. Operating primarily in Sweden, other European countries, and the United States, Hansa Biopharma generates the majority of its revenue from product sales.

Sivers Semiconductors AB, established in Sweden in 1951, specializes in the development, manufacturing, and sale of chips, components, modules, and subsystems based on advanced semiconductor technology. The company operates in two primary business areas: Wireless and Photonics. Its Wireless division focuses on high-frequency radio frequency integrated circuits (RFICs) for applications such as 5G millimeter wave networks, Wi-Fi meshed networks, and V2X communications. Meanwhile, the Photonics division concentrates on optical semiconductors for fiber networks, wireless optical networks, and sensors. Sivers serves customers globally, with a significant presence in North America, Europe, and Asia.

Ovzon is a company that specializes in mobile satellite services, offering advanced satellite-based mobile broadband solutions that integrate high data speeds with significant mobility. Utilizing patented technology, Ovzon meets the global connectivity needs of various sectors, including defense, media, navy, aviation, and non-governmental organizations. The company's innovative approach combines the advantages of mobile satellite telephony with the robust capacity of fixed satellite systems, ensuring reliable communication in remote and challenging environments.

Founded in 2003, Occlutech is a European hi-tech company specializing in developing and manufacturing cardiac occlusion devices and other vascular implants. The company focuses on improving the quality of life for patients with congenital and structural heart conditions, as well as stroke prevention.

Founded in 2014 by Fredrik Skantze and Per Made, Funnel is a software company specializing in marketing analytics. It integrates with over 400 data sources to automate data collection from various advertising platforms, catering to e-commerce companies, media agencies, brands, B2B businesses, mobile apps, and gaming companies.

Northvolt AB is a Swedish manufacturer of sustainable lithium‑ion batteries for electric vehicles, renewable energy storage, and industrial applications. Founded in 2016 and headquartered in Stockholm, the company designs and produces cells, custom cells, and complete battery systems with a focus on minimal carbon emissions and integrated recycling. Its production facilities combine research, industrialization, and end‑to‑end recycling technologies to deliver environmentally friendly batteries that support the transition to a decarbonized economy.

Ascelia Pharma is a biotechnology company based in Malmö, Sweden, dedicated to the development of oncology treatments, particularly for orphan diseases. The company specializes in creating novel drugs that target unmet medical needs and possess clear pathways for development and commercialization. Currently, Ascelia Pharma is advancing two drug candidates, Orviglance and Oncoral, which are in clinical development stages. The company's focus on rare cancers highlights its commitment to addressing significant gaps in treatment options within the oncology sector.

Saniona is a pharmaceutical company focused on discovering and developing medicines that modulate ion channels to treat central nervous system disorders, autoimmune diseases, metabolic diseases, and pain. It operates a technology platform that enables investigation of ion channel targets, including GABAA receptors, nicotinic acetylcholine receptors, and potassium channels, to create selective modulators. Its product pipeline includes Tesomet, SAN711, SAN903, and SAN2219; Tesomet has advanced to mid-stage trials for rare eating disorders, SAN711 completed a Phase 1 trial for neuropathic pain, SAN903 is positioned to enter Phase 1 trials for inflammatory and fibrotic disorders, and SAN2219 is in development. Saniona operates in the United States, Sweden, Germany, Denmark, and the United Kingdom.

Cinclus Pharma AG is a research-based biotech company focused on developing small molecules to treat gastric acid-related diseases, with a particular emphasis on gastroesophageal reflux disease (GERD). Their primary asset, X842, is designed to address severe erosive GERD and has undergone Phase I clinical trials. Additionally, the company is exploring a dual therapy treatment that combines an antibiotic targeting Helicobacter pylori bacteria. Cinclus Pharma AG operates from its headquarters in Basel, Switzerland.

iZettle AB is a financial technology company based in Stockholm, Sweden, that specializes in mobile payment services and applications designed for small businesses and entrepreneurs. Founded in 2010, it revolutionized the industry with the introduction of the first mini chip card reader, enabling businesses to accept card payments through smartphones and tablets. iZettle offers a range of products, including the iZettle Card Reader Lite and an application compatible with iOS and Android devices, which facilitate payment processing, business management, sales analytics, and customer engagement. The company serves a diverse clientele across several countries, including Sweden, Norway, Denmark, Finland, the United Kingdom, Germany, Spain, Mexico, the Netherlands, and Brazil. As of 2018, iZettle operates as a subsidiary of PayPal Holdings, Inc.